When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot. In a study of the three… read more.
Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.
Three-dimensional (3D) printing is a method of creating a 3D object layer-by-layer using computer-created design. It has been used to produce personalised bone grafts and dental implants but… read more.
A randomised, cross-over study has demonstrated bioequivalence of the 3D printed tablets with one commercial formulation but there are still additional hurdles to overcome before 3D printing of… read more.
Semi-solid extrusion (SSE) technology for tablets involves printing from a syringe filled with a gel or paste. Healthy volunteers felt that the resulting tablets were no different from… read more.
Three-dimensional (3D) printing is a method of creating a 3D object layer-by-layer using computer-created design. It has been used to produce personalised bone grafts and dental implants but… read more.
Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.
Triptan, ergot and anti-emetic medications appear to be two to five times more effective than ibuprofen for treating migraine, researchers reported on Nov. 29, 2023 in Neurology. “There… read more.
UCB announced that the European Commission (EC) has granted a marketing authorization for Zilbrysq (zilucoplan) as an add-on to standard therapy for the treatment of generalized myasthenia gravis… read more.
Vivos Therapeutics, Inc. announced that it has been granted 510(k) clearance from the FDA for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE… read more.
AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate) . The decision was made due to substantially increased enrolment… read more.
The Ministry of Health, Labor and Welfare (MHLW) on November 21 ordered label revisions for five anticoagulants to newly advise the risk of acute kidney injury, including Bristol… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
